Zanamivir.txt

CLINICAL USE

Treatment of influenza A and B within 48 hours after onset of symptoms Post exposure prophylaxis

DOSE IN NORMAL RENAL FUNCTION

Treatment: 10 mg twice daily for 5 days Prophylaxis: 10 mg once daily for 10 days

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 332.3

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :

<10 &nbsp &nbsp &nbsp &nbsp &nbsp :

%Excreted unchanged in urine &nbsp &nbsp : 100

Volume of distribution (L/kg) &nbsp &nbsp &nbsp : No data

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp : 2.6–5/Increased

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp: Unknown dialysability. Dose as in normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : Unknown dialysability. Dose as in normal renal function

HDF/high flux &nbsp : Unknown dialysability. Dose as in normal renal function

CAV/VVHD &nbsp &nbsp &nbsp: Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

Inhalation

Rate of Administration

–

Comments

–

OTHER INFORMATION

10 to 20

% of dose is systemically absorbed .